Auditory and Vestibular Functioning in Individuals with Type-2 Diabetes Mellitus: A Systematic Review

Kumar, Prawin; Singh, Niraj Kumar; Apeksha, Kumari; Ghosh, Vipin; Kumar, Raveendran Rajesh; Muthaiah, Bhanu Kumar

doi:10.1055/s-0041-1726041

Cited by 9 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Major contributing factors for vestibular impairment in hypertension and diabetes are microangiopathic effects, such as ischemia of the vestibular microcirculation, alteration of the metabolism of the inner ear fluid, and loss of type-I hair cells in the saccule. 29 , 30 They mainly cause vestibular nerve signal transduction and vestibular organ structure changes. However, the evidence for their involvement in the etiology of vestibular neuritis is not strong.…”

Section: Discussionmentioning

confidence: 99%

Objective Neurological Testing Methods Used to Follow Up Vestibular Neuritis Depending on Different Factors

Li,

Miao,

Zhang

et al. 2023

IJGM

View full text Add to dashboard Cite

Purpose We analyze the impact of different factors on clinical performance and prognosis in vestibular neuritis (VN) and explore indicators that could accurately reflect changes in patients’ symptoms at different stages. Methods We observed patients with VN during the acute and recovery phases. Clinical symptoms, vertigo-related scales, neurological examination, vestibular function tests (caloric test, video head impulse test (vHIT), vestibular evoked myogenic potential (VEMP)), and the history of disease (underlying diseases, glucocorticoid therapy) were recorded at onset and at 4 and 12 weeks after onset in VN patients. Multiple linear regression analysis was used to identify vestibular function tests that had a linear regression relationship with the subjective quantitative results. Results At 4 weeks after onset, the group without underlying disease had better improvement in EEV, gain, and UW than the group with underlying disease (P < 0.05). There was a significant difference in the change in DHI, EEV, gain of the affected horizontal semicircular canal in the vHIT and unilateral weakness (UW) between the glucocorticoid treatment group and the no glucocorticoid treatment group (P < 0.05), and glucocorticoid treatment group was better. The change value in the gain of horizontal canals in the vHIT was mainly positively and linearly correlated with the EEV scores (P<0.001). Possible dynamic correlation between vHIT results and vestibular symptoms. Conclusion The absence of underlying disease and the receipt of glucocorticoid therapy significantly contributed to the improvement of objective vestibular function tests in the short term, while the improvement of subjective vertigo may correlate with the different objective measures and questionnaire. We believe that the improvement of the affected horizontal semicircular canal gain value in the vHIT can be used as a reference indicator of the degree of improvement of vestibular symptoms with superior vestibular neuritis.

show abstract

Section: Discussionmentioning

confidence: 99%

Objective Neurological Testing Methods Used to Follow Up Vestibular Neuritis Depending on Different Factors

Li,

Miao,

Zhang

et al. 2023

IJGM

View full text Add to dashboard Cite

show abstract

“…The subjects were instructed to look up at a distant target in the midline, the electrodes were aligned with the center of the pupil. To allow for this close electrode insertion, the electrode is then stuck with micropore tape over the electrode, making sure that no electrical bridge forms between the two electrodes (Kumar et al, 2021).…”

Section: Equipmentmentioning

confidence: 99%

“…Previous studies have primarily focused on assessing otolith dysfunction and conducting audio-vestibular profiling in individuals with T2DM, yet there remains a notable gap in understanding the specific mechanisms underlying vestibular dysfunction in this population (DiLiberto et al, 2024;Kumar et al, 2021). Consequently, it remains unclear whether T2DM affects the tuning of the vestibular system.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Altered Frequency Dynamics of Ocular-Vestibular Evoked Myogenic Potentials in Type 2 Diabetes Mellitus

Seshagiri,

Purushothaman,

Thirunavukkarasu

et al. 2024

Audiol Speech Res

View full text Add to dashboard Cite

Purpose: The study aims to address the gap in understanding the relationship between type 2 diabetes mellitus (T2DM) and vestibular dysfunction, particularly focusing on how T2DM may affect the tuning of the vestibular system. Specifically, the investigation aims to explore the impact of stimulus parameters, particularly stimulus frequency, on ocular vestibular evoked myogenic potentials (oVEMP) in individuals with T2DM.Methods: A case-control study design was used, utilizing non-probability sampling. All participants underwent routine audiological and vestibular evaluations before inclusion in the study. oVEMP’s were compared across 40 healthy individuals (group A) and 40 individuals with T2DM (group B) at 500 Hz, 1 KHz, and 2 KHz.Results: In group A, all 80 participants exhibited oVEMP responses across all frequencies in both ears, while in group B, consisting of individuals with T2DM, response rates were slightly lower, ranging from 70% to 77.5% across frequencies. Statistical analysis revealed significant amplitude differences at all frequencies tested in type 2 diabetic ears compared to healthy ears, although amplitude remained consistent within type 2 diabetic ears. Latencies (first negative [N1] and first positive [P1]) were consistent across groups, with delays observed in P1 latency, particularly noticeable at higher frequencies, both in healthy and type 2 diabetic ears. Gender didn't affect oVEMP frequency dynamics in any of the groups.Conclusion: Diabetes may create an impact in the functioning of otolith organs, the vestibular branch of eighth cranial nerve, and their innervations. VEMP evaluates both the sacculo-collic and utriculo-ocular pathways to detect changes in the functions of vestibular organs. Therefore, it's crucial to consider diabetes when conducting vestibular diagnosis or treatment.

show abstract

“…Унаслідок пошкодження мієлінової оболонки у синаптичних ділянках слухового аналізатора спостерігається порушення нейрональних клітин та розлади проведення сигналу на ретрокохлеарній ділянці [17,18]. Окрім цього, концентрація ПМБ 22 у сироватці крові відображає ступінь ураження мієлінової оболонки нейроцитів, тому може бути використана як ранній маркер ушкоджень невральних структур у хворих на ЦД 2-го типу, зокрема сенсоневральної приглухуватості (СНП) [19].…”

Section: вступunclassified

Impairment of auditory function in persons with type 2 diabetes mellitus depending on the level of peripheral myelin protein 22

Shydlovska,

Navalkivska,

Kostitska

2023

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Background. One of the priority tasks of modern medicine is early diagnosis and treatment of micro- and macrovascular complications of diabetes mellitus (DM) which cause a decrease in the quality of life of working age people and an increase in mortality. Variability of carbohydrate metabolism indicators, metabolic dysfunction are leading factors in the development and progression of disabling complications of type 2 DM with hearing loss due to degenerative changes in nerve fibers. An important aspect of diagnostic and treatment algorithms of sensorineural hearing disorders in patients with type 2 DM is early detection of demyelinating processes to prevent damage to neuronal structures. The purpose of the study is to determine the relationship between the level of peripheral myelin protein 22 (PMP 22) and the condition of the auditory analyzer according to the data of instrumental examination in patients with type 2 DM combined with hearing impairment. Materials and methods. There were examined 30 patients with type 2 DM (15 men and 15 women aged 56.28 ± 4.54 years) associated with degree I–II sensorineural disorders of the auditory function; 15 people with signs of sensorineural hearing loss (SNHL) (8 men, 7 women aged 59.33 ± 2.65 years) without diabetes and 15 controls. During the examination, the patients with type 2 DM and SNHL, depending on the severity of the underlying disease, were divided into groups: the first group (n = 15) with or without isolated microvascular complications of type 2 DM, the second group (n = 15) with neuro-, nephro- and retinopathy. All patients underwent a set of laboratory tests to determine the content of PMP 22 in the blood serum, clinical and instrumental diagnosis of the auditory function. The obtained data were processed statistically, and correlations were identified. Results. The analysis of the results revealed that in patients with type 2 DM and SNHL (groups 1 and 2), the level of peripheral myelin protein 22 significantly increased compared to both controls and the comparison group, and more significantly in those with microangiopathies. The correlations were found between the most informative indicators reflecting the state of various structures of the hearing analyzer and the content of PMP 22 in the blood serum. Conclusions. A significant increase was revealed in the content of PMP 22 and manifestations of sensorineural hearing loss in patients with type 2 diabetes mellitus associated with microangiopathies that indicate demyelinating processes in the neural structures of the auditory analyzer.

show abstract

Auditory and Vestibular Functioning in Individuals with Type-2 Diabetes Mellitus: A Systematic Review

Cited by 9 publications

References 48 publications

Objective Neurological Testing Methods Used to Follow Up Vestibular Neuritis Depending on Different Factors

Objective Neurological Testing Methods Used to Follow Up Vestibular Neuritis Depending on Different Factors

Efficacy of Altered Frequency Dynamics of Ocular-Vestibular Evoked Myogenic Potentials in Type 2 Diabetes Mellitus

Impairment of auditory function in persons with type 2 diabetes mellitus depending on the level of peripheral myelin protein 22

Contact Info

Product

Resources

About